Cycloamylose-nanogel drug delivery system-mediated intratumor silencing of the vascular endothelial growth factor regulates neovascularization in tumor microenvironment

Cancer Science

Volumn 105, Issue 12, 2014, Pages 1616-1625

  Fujii, Hidetaka ^a   Shin Ya, Masaharu ^a   Takeda, Shigeo ^b   Hashimoto, Yoshihide ^b,c   Mukai, Sada Atsu ^b,c   Sawada, Shin Ichi ^b,c   Adachi, Tetsuya ^a   Akiyoshi, Kazunari ^b,c   Miki, Tsuneharu ^a   Mazda, Osam ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Drug delivery system; Nanogel; Renal cell carcinoma; RNA interference; Vascularendothelial growth factor

Indexed keywords

CYCLODEXTRIN; MACROGOL DERIVATIVE; NANOGEL; POLYETHYLENEIMINE; SMALL INTERFERING RNA; VASCULOTROPIN A;

ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY SPECIFICITY; CARCINOMA, RENAL CELL; CHEMISTRY; DRUG DELIVERY SYSTEM; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENE THERAPY; HUMAN; KIDNEY NEOPLASMS; MOUSE; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; VASCULARIZATION;

ANIMALS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CYCLODEXTRINS; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; KIDNEY NEOPLASMS; MICE; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; ORGAN SPECIFICITY; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; RNA, SMALL INTERFERING; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84917709397     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12547     Document Type: Article

References (30)

1. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: Double-stranded RNA directs theATP-dependent cleavage of mRNAat 21 to 23 nucleotide intervals. Cell 2000; 101: 25-33.
2. Gartel AL, Kandel ES. RNA interference in cancer. Biomol Eng 2006; 23: 17-34.
3. Miele E, Spinelli GP, Di Fabrizio E, Ferretti E, Tomao S, Gulino A. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomedicine 2012; 7: 3637-57.
4. Ito T, Yoshihara C, Hamada K, Koyama Y. DNA/polyethyleneimine/hyaluronic acid small complex particles and tumor suppression in mice. Biomaterials 2010; 31: 2912-8.
5. Sasaki Y, Akiyoshi K. Nanogel engineering for new nanobiomaterials: From chaperoning engineering to biomedical applications. Chem Rec 2010; 10: 366-76.
6. Kabanov AV, Vinogradov SV. Nanogels as pharmaceutical carriers: Finite networks of infinite capabilities. Angew Chem Int Ed Engl 2009; 48: 5418-29.
7. Toita S, Soma Y, Morimoto N, Akiyoshi K. Cycloamylose-based biomaterial: nanogel of cholesterol-bearing cationic cycloamylose for siRNA delivery. Chem Lett 2009; 38: 1114-5.
8. Toita S, Sawada S, Akiyoshi K. Polysaccharide nanogel gene delivery system with endosome-escaping function: Co-delivery of plasmid DNA and phospholipase A2. J Control Release 2011; 155: 54-9.
9. Saenger W, Jacob J, Gessler K et al. Structures of the common cyclodextrins and their larger analogues-beyond the doughnut. Chem Rev 1998; 98: 1787-802.
10. Tomono K, Mugishima A, Suzuki T et al. Interaction between cycloamylose and various drugs. J Incl Phenom Macrocycl Chem 2002; 44: 267-70.
11. Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004; 64: 3365-70.
12. Nagaraj S, Gabrilovich DI. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 2008; 68: 2561-3.
13. Rolf AB, Jay PO, Victor AS et al. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2(KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumorgrowth in mice. Cancer Res 2000; 60: 5117-24.
14. Verheul HM, Hammers H, van Erp K et al. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res 2007; 13: 4201-8.
15. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-74.
16. Eisen T, Sternberg CN, Robert C et al. Targeted therapies for renal cell carcinoma: Review of adverse event management strategies. J Natl Cancer Inst 2012; 104: 93-113.
17. Chen J, Tian H, Dong X et al. Effective tumor treatment by VEGF siRNA complexed with hydrophobic poly(amino acid)-modified polyethylenimine. Macromol Biosci 2013; 13: 1438-46.
18. Chen CJ, Wang JC, Zhao EY et al. Self-assembly cationic nanoparticles based on cholesterol-grafted bioreducible poly(amidoamine) for siRNA delivery. Biomaterials 2013; 34: 5303-16.
19. Nochi T, Yuki Y, Takahashi H et al. Nanogel antigenic protein-delivery system foradjuvant-free intranasal vaccines. Nat Mater 2010; 9: 572-8.
20. Christina LR, Kristi DL, Jason ET et al. Cytokine levels correlate with immune cell infiltrationafter anti-VEGF therapy in preclinical mouse models ofbreast cancer. PLoS ONE 2009; 4: e7669.
21. Shojaei F, Wu X, Malik AK et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007; 25: 911-20.
22. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010; 70: 6171-80.
23. Tu S, Bhagat G, Cui G et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008; 14: 408-19.
24. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-74.
25. Dolcetti L, Marigo I, Mantelli B, Peranzoni E, Zanovello P, Bronte V. Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett 2008; 267: 216-25.
26. Tu SP, Jin H, Shi JD et al. Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. Cancer Prev Res 2012; 5: 205-15.
27. Kusmartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 2006; 55: 237-45.
28. Nakamura I, Shibata M, Gonda K et al. Serum levels of vascular endothelial growth factor are increased and correlate with malnutrition, immunosuppression involving MDSCs and systemic inflammation in patients with cancer of the digestive system. Oncollett 2013; 5: 1682-6.
29. Satoh T, Tajima M, Wakita D, Kitamura H, Nishimura T. The development of IL-17/IFN-gamma-double producing CTLs from Tc17 cells is driven by epigenetic suppression of socs3 gene promoter. Eur J Immunol 2012; 42: 2329-42.
30. Das RL, Pathangey LB, Tinder TL, Schettini JL, Gruber HE, Mukherjee P. Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis. Breast Cancer Res 2009; 11: R56.